David M. Polen
Polen Capital Management
Polen Capital Management Cantel Medical Corp stake
total: 588
Polen Capital Management CMD trades
- Total transactions:
- 10
- New positions:
- 1
- Sold out:
- 1
- Added:
- 8
- Held since:
- 2017 Q3
- Held for:
- 9 quarters
- Latest activity:
- 2019 Q4
According to 2026 Q2 report, Polen Capital Management doesn't hold any Cantel Medical Corp (CMD) shares. To date, the estimated cost basis is nearly $89.7 for "buy" trades and estimated average "sell" price is $74.78. Polen Capital Management first purchased CMD in 2017 Q3, initially acquiring 2,286 shares. Since the initial investment in Cantel Medical Corp (CMD), Polen Capital Management has made 9 more transactions.
When did Polen Capital Management sell Cantel Medical Corp (CMD)?
Polen Capital Management sold off the entire Cantel Medical Corp (CMD) position in 2019 Q4.
When did Polen Capital Management buy Cantel Medical Corp (CMD)?
Polen Capital Management first invested in Cantel Medical Corp (CMD) in 2017 Q3 at the reported quarter-end price of $94.05 per share.
What's the cost basis of Polen Capital Management's CMD stake?
The estimated cost basis for Cantel Medical Corp (CMD) stake is around $89.70 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $89.70
- Weighted AVG sell price:
- $74.78
Polen Capital Management's historical trades in Cantel Medical Corp
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2019 Q4
|
0.00%
|
$74.78
|
-100% (-12,115)
|
|||
|
2019 Q3
|
0.00%
|
$74.78
|
+1.36% (+163)
|
|||
|
2019 Q2
|
0.00%
|
$80.66
|
+7.67% (+851)
|
|||
|
2019 Q1
|
0.00%
|
$66.93
|
+8.34% (+855)
|
|||
|
2018 Q4
|
0.00%
|
$74.47
|
+44.92% (+3,176)
|
|||
|
2018 Q3
|
0.00%
|
$91.94
|
+9.19% (+595)
|
|||
|
2018 Q2
|
0.00%
|
$98.38
|
+12.14% (+701)
|
|||
|
2018 Q1
|
0.00%
|
$111.36
|
+42.50% (+1,722)
|
|||
|
2017 Q4
|
0.00%
|
$102.91
|
+77.25% (+1,766)
|
|||
|
2017 Q3
|
0.00%
|
$94.05
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.